search
Back to results

Study of Purified Vero Rabies Vaccine Serum Free Compared With Reference Purified Vero Rabies Vaccine in Healthy Adults

Primary Purpose

Rabies

Status
Completed
Phase
Phase 2
Locations
France
Study Type
Interventional
Intervention
Purified Vero Rabies Vaccine - Serum Free
Purified inactivated rabies vaccine
Sponsored by
Sanofi Pasteur, a Sanofi Company
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Rabies focused on measuring Rabies, Rabies virus, Purified Vero Rabies Vaccine, Serum Free

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria :

  • Aged 18 to 60 years on the day of inclusion
  • Provision of a signed Informed Consent Form
  • Able to attend all scheduled visits and comply with all trial procedures
  • For a woman of child-bearing potential, avoid becoming pregnant (use of an effective method of contraception or abstinence for at least 4 weeks prior to each vaccination, until at least 4 weeks after each vaccination)
  • Entitlement to national social security

Exclusion Criteria :

  • For a woman of child-bearing potential, known pregnancy or positive urine pregnancy test
  • Breast-feeding woman
  • Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the first trial vaccination
  • Planned participation in another clinical trial during the present trial period
  • Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy
  • Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or to a vaccine containing any of the same substances
  • Chronic illness, at a stage that could interfere with trial conduct or completion, in the opinion of the Investigator
  • Current alcohol abuse or drug addiction that may interfere with the subject's ability to comply with trial procedures
  • Receipt of blood or blood-derived products in the past 3 months, that might interfere with the assessment of immune response
  • Receipt of any vaccine in the 4 weeks preceding the first trial vaccination
  • Planned receipt of any vaccine in the 4 weeks following any trial vaccination
  • Known human immunodeficiency virus (HIV), Hepatitis B surface (HBs) antigen, or Hepatitis C seropositivity
  • Previous vaccination against rabies with any vaccine (in pre- or post-exposure regimen)
  • Thrombocytopenia, bleeding disorder or anticoagulants in the 3 weeks preceding inclusion contraindicating intramuscular (IM) vaccination
  • Subject at high risk for rabies exposure during the trial period
  • Subjects deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent
  • Febrile illness (temperature ≥38.0°C) or moderate or severe acute illness/infection on the day of vaccination, according to Investigator judgment.
  • Study site employee who is involved in the protocol and may have direct access to trial related data.

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

VRVg Group

Verorab Group

Arm Description

Outcomes

Primary Outcome Measures

To provide information concerning the immunogenicity of Purified Vero Rabies Vaccine.

Secondary Outcome Measures

To provide information concerning the safety after Purified Vero Rabies Vaccine.

Full Information

First Posted
July 28, 2009
Last Updated
May 27, 2014
Sponsor
Sanofi Pasteur, a Sanofi Company
search

1. Study Identification

Unique Protocol Identification Number
NCT00948272
Brief Title
Study of Purified Vero Rabies Vaccine Serum Free Compared With Reference Purified Vero Rabies Vaccine in Healthy Adults
Official Title
Immunogenicity of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Reference Purified Vero Rabies Vaccine in Pre-exposure Use in Healthy Adults
Study Type
Interventional

2. Study Status

Record Verification Date
May 2014
Overall Recruitment Status
Completed
Study Start Date
July 2009 (undefined)
Primary Completion Date
February 2011 (Actual)
Study Completion Date
August 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sanofi Pasteur, a Sanofi Company

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to generate data in human on immunogenicity and safety of Purified Vero Rabies Vaccine (VRVg) in support of the vaccine registration. Primary Objective: To demonstrate that VRVg is at least as immunogenic as the reference vaccine, Verorab, in terms of seroconversion rate at Day 42 of the primary vaccination series. Secondary Objectives: To assess the clinical safety of VRVg after each vaccination when administered in a pre-exposure vaccination schedule with a booster at 12 months after the first vaccination in all subjects. To describe the immune response induced by VRVg 21 days after two vaccinations in a subset of randomized subjects and 14 days after the last vaccination of the primary vaccination series.
Detailed Description
All subjects will receive three vaccinations for primary series and a booster vaccination at 12 months after the first vaccination.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rabies
Keywords
Rabies, Rabies virus, Purified Vero Rabies Vaccine, Serum Free

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
384 (Actual)

8. Arms, Groups, and Interventions

Arm Title
VRVg Group
Arm Type
Experimental
Arm Title
Verorab Group
Arm Type
Active Comparator
Intervention Type
Biological
Intervention Name(s)
Purified Vero Rabies Vaccine - Serum Free
Other Intervention Name(s)
VRVg
Intervention Description
0.5 mL, Intramuscular
Intervention Type
Biological
Intervention Name(s)
Purified inactivated rabies vaccine
Other Intervention Name(s)
Verorab
Intervention Description
0.5 mL, Intramuscular
Primary Outcome Measure Information:
Title
To provide information concerning the immunogenicity of Purified Vero Rabies Vaccine.
Time Frame
42 days post-primary series vaccination
Secondary Outcome Measure Information:
Title
To provide information concerning the safety after Purified Vero Rabies Vaccine.
Time Frame
0 to 7 days post-vaccination and entire study duration

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria : Aged 18 to 60 years on the day of inclusion Provision of a signed Informed Consent Form Able to attend all scheduled visits and comply with all trial procedures For a woman of child-bearing potential, avoid becoming pregnant (use of an effective method of contraception or abstinence for at least 4 weeks prior to each vaccination, until at least 4 weeks after each vaccination) Entitlement to national social security Exclusion Criteria : For a woman of child-bearing potential, known pregnancy or positive urine pregnancy test Breast-feeding woman Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the first trial vaccination Planned participation in another clinical trial during the present trial period Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or to a vaccine containing any of the same substances Chronic illness, at a stage that could interfere with trial conduct or completion, in the opinion of the Investigator Current alcohol abuse or drug addiction that may interfere with the subject's ability to comply with trial procedures Receipt of blood or blood-derived products in the past 3 months, that might interfere with the assessment of immune response Receipt of any vaccine in the 4 weeks preceding the first trial vaccination Planned receipt of any vaccine in the 4 weeks following any trial vaccination Known human immunodeficiency virus (HIV), Hepatitis B surface (HBs) antigen, or Hepatitis C seropositivity Previous vaccination against rabies with any vaccine (in pre- or post-exposure regimen) Thrombocytopenia, bleeding disorder or anticoagulants in the 3 weeks preceding inclusion contraindicating intramuscular (IM) vaccination Subject at high risk for rabies exposure during the trial period Subjects deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent Febrile illness (temperature ≥38.0°C) or moderate or severe acute illness/infection on the day of vaccination, according to Investigator judgment. Study site employee who is involved in the protocol and may have direct access to trial related data.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Director
Organizational Affiliation
Sanofi Pasteur Inc.
Official's Role
Study Director
Facility Information:
City
Gières
ZIP/Postal Code
38610
Country
France
City
Montpellier Cedex 5
ZIP/Postal Code
34094
Country
France
City
Pierre Bénite
ZIP/Postal Code
69130
Country
France
City
Poitiers
ZIP/Postal Code
86000
Country
France
City
Rennes
ZIP/Postal Code
35000
Country
France
City
Rueil Malmaison
ZIP/Postal Code
92502
Country
France

12. IPD Sharing Statement

Citations:
PubMed Identifier
23510665
Citation
Pichon S, Guinet-Morlot F, Minutello M, Donazzolo Y, Rouzier R, Chassard D, Fitoussi S, Hou V. A serum-free, purified vero cell rabies vaccine is safe and as immunogenic as the reference vaccine Verorab for pre-exposure use in healthy adults: results from a randomized controlled phase-II trial. Vaccine. 2013 Apr 26;31(18):2295-301. doi: 10.1016/j.vaccine.2013.02.058. Epub 2013 Mar 16.
Results Reference
result
Links:
URL
http://www.sanofipasteur.com
Description
Related Info

Learn more about this trial

Study of Purified Vero Rabies Vaccine Serum Free Compared With Reference Purified Vero Rabies Vaccine in Healthy Adults

We'll reach out to this number within 24 hrs